Antares Pharma Inc (ATRS)

NASDAQ
5.590
0.000(0.00%)
  • Volume:
    0
  • Day's Range:
    5.580 - 5.600
  • 52 wk Range:
    3.110 - 5.600
Trading near 52-week High

ATRS Overview

Prev. Close
5.59
Day's Range
5.58-5.6
Revenue
183.46M
Open
5.58
52 wk Range
3.11-5.6
EPS
0.237
Volume
0
Market Cap
955.07M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
5,247,050
P/E Ratio
24.11
Beta
1.16
1-Year Change
47.49%
Shares Outstanding
170,852,427
Next Earnings Date
-
What is your sentiment on Antares?
or
Vote to see community's results!

Antares Pharma Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Antares Pharma Inc Analysis

Antares Pharma Inc Company Profile

Antares Pharma Inc Company Profile

Employees
202

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company’s injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellBuyStrong BuyStrong Buy
Technical IndicatorsSellBuyStrong BuyStrong BuyStrong Buy
SummaryStrong SellNeutralStrong BuyStrong BuyStrong Buy
  • This stock is looking good to enter soon!
    0
    • is it good ?
      0
      • i am back .
        0
        • why this stock hasnt gone up after the last ER is a mystery to me... well, let's keep buying at this bargain price
          0
          • next level: 4.20
            0
            • you got it right !
              0
            • you got it right !
              0
          • What˘s the news? :-)
            0
            • time to buy
              0
              • antare pharma inc ? you think is a good stock to invest ? best regards, Ian King from Bulgaria.
                0
                • overpriced garbage
                  3
                  • Poor bear, RIP
                    0
                  • hello Mr. Hicks, do you think is a good case to buy now Antares ?
                    0
                  • Wow you sure did a good job with your speculation. Lol
                    0